By Dr. Avishek Kumar
When someone hears there may finally be a breakthrough for pancreatic cancer, the natural reaction is hope.
In clinic, however, I often see what comes next.
The frantic Googling. The late-night searches. The confusion. Sometimes despair.
And one overwhelming question:
“Could this help me or someone I love?”
Exciting cancer news only matters if patients understand two things:
Who the treatment is actually for. And how to access it.
That is why the excitement around daraxonrasib matters. But also why patients need to understand what this drug is, and what it is not.
First, some context.
Pancreatic cancer has historically been one of the hardest cancers to treat.
Why?
Because it is often silent.
Many patients have no symptoms at all early on. No pain. No warning sign. The cancer can quietly grow for months or years. By the time symptoms appear, things like unexplained weight loss, jaundice, abdominal pain, or fatigue, the disease has often already spread.
In many cases, pancreatic cancer is diagnosed after it has become metastatic or is no longer surgically removable.
That is what has made this disease so devastating.
For years, our main tools were chemotherapy combinations. Treatments like FOLFIRINOX or gemcitabine-based regimens have helped many patients live longer and better, but outcomes in advanced disease have remained frustratingly limited.
And while immunotherapy has transformed cancers like lung cancer, melanoma, and even some breast cancers, most pancreatic cancers have remained frustratingly resistant. The same treatments that can produce dramatic responses elsewhere often barely move the needle in pancreatic cancer, with a few important exceptions such as MSI-high tumors.
That is exactly why the excitement around targeted therapies matters.
For the first time, we are beginning to see treatments designed around the biology of the cancer itself.
And that brings us to daraxonrasib.
Daraxonrasib is promising because it targets a pathway in cancer that researchers struggled for years to effectively drug. For the right patient, this may represent a meaningful step forward.
But here is the critical point:
This is not a drug for everyone with pancreatic cancer.
The most important question a patient should ask their oncologist right now is this:
“Has my tumor had comprehensive molecular testing?”
In 2026, pancreatic cancer treatment is becoming increasingly personalized.
Two patients may appear to have the same diagnosis on a scan. Yet their cancers may behave very differently at a molecular level. One patient may qualify for a targeted therapy or clinical trial. Another may not.
Without the right testing, patients may never even know those opportunities exist.
I tell patients this all the time:
The biopsy is no longer just about proving it is cancer. It is about understanding the cancer.
Now let’s talk about the question many families are really asking:
“How do we actually get access to this drug?”
Right now, daraxonrasib is still investigational. That means access is generally through a clinical trial or, in select cases, an Expanded Access Program, sometimes called compassionate use.
Patients cannot request it on their own. Your oncologist helps lead the process.
Typically, patients being considered have advanced pancreatic cancer, have already received standard therapies, and are not eligible for an active clinical trial.
The first step is simple:
Ask your oncologist directly, “Am I a candidate for daraxonrasib or a related clinical trial?”
If the answer may be yes, your oncology team can help explore trials or request access when appropriate.
And here is the hopeful part.
In oncology, promising drugs that show meaningful benefit often become easier to access over time. What begins in clinical trials can eventually become standard treatment for the right patients.
We are not fully there yet. But for pancreatic cancer, this is one reason many oncologists are watching this space so closely.
I am optimistic about where pancreatic cancer care is heading.
The future will not be one miracle drug.
It will be smarter treatment. Matching the right patient to the right therapy at the right time.
And for many families, that conversation should start today.
Dr. Avishek Kumar
Board-Certified Medical Oncologist
https://www.regionalcancercare.org/physicians/avishek-kumar-md/
About Dr. Avishek Kumar:
Dr. Avishek Kumar is a board-certified medical oncologist based in Edison, NJ (NYC metro). He focuses on modern, evidence-based cancer treatment, second opinions, and infusion therapies. He also serves as a Lieutenant Colonel in the U.S. Air Force Reserve as a flight surgeon. He has deployed overseas and regularly flies on fighter aircraft in support of operational missions, bringing a high-performance, mission-driven mindset to medicine and leadership.
